BioVie (BIVI) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
3 Feb, 2026Opening remarks and agenda
Meeting called to order by the Chairman, with all directors, key executives, independent accountant, and outside counsel present virtually.
Polls opened for voting on all matters to be presented.
Corporate governance
Record date for voting set as September 22, 2025, with 7,535,080 shares outstanding, each entitled to one vote.
Quorum established with over 45% of shares represented virtually or by proxy.
Inspector of Election appointed and sworn in to oversee voting and tally results.
Board and executive committee updates
Six directors nominated and elected for a one-year term: Jim Lang, Cuong Do, Michael Sherman, Sigmund Rojich, Amy Chappell, and Kameel Farag.
Partial view of Summaries dataset, powered by Quartr API
Latest events from BioVie
- Biotech seeks to raise up to $300M for neuro and liver disease R&D via flexible securities offering.BIVI
Registration filing18 Jun 2026 - Imminent clinical data for Parkinson's and Long COVID could unlock major market opportunities.BIVI
Investor update2 Jun 2026 - Bezisterim and BIV201 show promising efficacy in neurodegenerative and liver disease trials.BIVI
Corporate presentation2 Jun 2026 - Bezisterim targets neuroinflammation and metabolic dysregulation to address Parkinson's progression.BIVI
KOL event14 May 2026 - Net loss widened to $5.3M for the quarter as R&D spending rose, with cash at $13.1M.BIVI
Q3 202611 May 2026 - Lead therapies show strong efficacy in neurodegeneration and ascites, with high commercial potential.BIVI
Corporate presentation23 Apr 2026 - Imminent clinical data for Parkinson's and long COVID could unlock major market opportunities.BIVI
Biotech Resurgence: Platforms and Pipelines of Today's Innovators16 Apr 2026 - Phase II data for Parkinson's and long COVID expected in 2024; BIV201 phase III planning underway.BIVI
Status update4 Mar 2026 - Net loss narrowed, cash bolstered by $10.5M raise, but going concern risks persist.BIVI
Q2 20266 Feb 2026